Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Trial of D2C7-IT in Combination With an Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11) Administered Intratumorally Via Convection-Enhanced Delivery Followed by Perilymphatic Injections of 2141-V11 and Assessment of the Tumor Monorail for Adult Patients With Recurrent Malignant Glioma

Next Previous
Trial Profile

A Phase 1 Trial of D2C7-IT in Combination With an Fc-engineered Anti-CD40 Monoclonal Antibody (2141-V11) Administered Intratumorally Via Convection-Enhanced Delivery Followed by Perilymphatic Injections of 2141-V11 and Assessment of the Tumor Monorail for Adult Patients With Recurrent Malignant Glioma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 2141-V11 (Primary) ; D2C7-IT (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; First in man

Most Recent Events

  • 07 Jan 2026 company highlighted ongoing enrollment in a Phase 1 clinical trial at the Preston Robert Tisch Brain Tumor Center at Duke University. Early results indicate a favorable safety profile for Exvade's Tumor Monorail™, an FDA Breakthrough Device designed to provide physicians with safe, real-time access to brain tumors and their evolving microenvironment throughout treatment.
  • 03 Mar 2025 Planned End Date changed from 1 Dec 2025 to 1 Jun 2027.
  • 03 Mar 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top